Open AccessDetection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma
Author(s) -
Yoneda Kazue,
Kuwata Taiji,
Chikaishi Yasuhiro,
Mori Masataka,
Kanayama Masatoshi,
Takenaka Masaru,
Oka Soichi,
Hirai Ayako,
Imanishi Naoko,
Kuroda Koji,
Ichiki Yoshinobu,
Ohnaga Takashi,
Tanaka Fumihiro
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13895
Subject(s) - circulating tumor cell , medicine , receiver operating characteristic , mesothelioma , podoplanin , pathology , oncology , cancer , cancer research , immunohistochemistry , metastasis
Detection of rare tumor cells circulating in the blood ( CTC s) presents technical challenges. CellSearch, the only approved system for clinical use, fails to capture epithelial cell adhesion molecule‐negative CTC s such as malignant pleural mesothelioma ( MPM ). We have developed a novel microfluidic device ( CTC ‐chip) in which any Ab to capture CTC s is conjugated. The CTC ‐chip was coated with an Ab against podoplanin that is abundantly expressed on MPM . Circulating tumor cell ‐detection performance was evaluated in experimental models in which MPM cells were spiked in blood sampled from a healthy volunteer and in clinical samples drawn from MPM patients. The CTC ‐chip showed superior CTC ‐detection performance over CellSearch in experimental models (sensitivity, 63.3%‐64.5% vs 0%‐1.1%; P < .001) and in clinical samples ( CTC ‐positivity, 68.8% vs 6.3%; P < .001). A receiver operating characteristic ( ROC ) analysis showed that the CTC test provided a significant diagnostic performance in discrimination of unresectable disease from resectable disease (area under the ROC curve, 0.851; P = .003). The higher CTC count (≥2 cells/mL) was significantly associated with a poor prognosis ( P = .030). The novel CTC ‐chip enabled sensitive detection of CTC s, which provided significant diagnostic and prognostic information in MPM .